Search research articles
Contact Us
Filters
Showing results (281-290 of 353) with videos related to
Page
of 36
Sort By:
Poultry Science
|
February 8, 2022
Assessing growth performance, morphometric traits, meat chemical composition and cholesterol content in four phenotypes of naked neck chicken
M Shafiq, M T Khan, M S Rehman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 18, 2025
Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [<sup>68</sup>Ga]PSMA-11 or [<sup>18</sup>F]DCFPyL, [<sup>18</sup>F]FDG, and [<sup>177</sup>Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network
Price Jackson, James P Buteau, Lachlan McIntosh, et al.
European Urology
|
February 6, 2018
Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer
Sarah Q To, Edmond M Kwan, Heidi C Fettke, et al.
Genome Biology
|
January 28, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
Nada Lallous, Stanislav V Volik, Shannon Awrey, et al.
Contemporary Clinical Trials Communications
|
May 11, 2023
NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial
Muhammad Ali, Simon Wood, David Pryor, et al.
European Urology
|
February 3, 2026
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients
Andrew J Armstrong, Daniel P Petrylak, Neal D Shore, et al.
Prostate Cancer and Prostatic Diseases
|
August 22, 2021
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Arun A Azad, Andrew J Armstrong, Antonio Alcaraz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2022
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
Ebiomedicine
|
August 7, 2023
BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype
Heidi Fettke, Chao Dai, Edmond M Kwan, et al.
BJU International
|
November 13, 2022
Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer
Richard Kelly, Andrew Jensen, Nathasha Karunaratna, et al.
Page
of 36
Search research articles
Search
Showing results (281-290 of 353) with videos related to
Sort By:
Page
of 36
Poultry Science
|
February 8, 2022
Assessing growth performance, morphometric traits, meat chemical composition and cholesterol content in four phenotypes of naked neck chicken
M Shafiq, M T Khan, M S Rehman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 18, 2025
Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [<sup>68</sup>Ga]PSMA-11 or [<sup>18</sup>F]DCFPyL, [<sup>18</sup>F]FDG, and [<sup>177</sup>Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network
Price Jackson, James P Buteau, Lachlan McIntosh, et al.
European Urology
|
February 6, 2018
Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer
Sarah Q To, Edmond M Kwan, Heidi C Fettke, et al.
Genome Biology
|
January 28, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
Nada Lallous, Stanislav V Volik, Shannon Awrey, et al.
Contemporary Clinical Trials Communications
|
May 11, 2023
NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial
Muhammad Ali, Simon Wood, David Pryor, et al.
European Urology
|
February 3, 2026
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients
Andrew J Armstrong, Daniel P Petrylak, Neal D Shore, et al.
Prostate Cancer and Prostatic Diseases
|
August 22, 2021
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Arun A Azad, Andrew J Armstrong, Antonio Alcaraz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2022
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
Ebiomedicine
|
August 7, 2023
BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype
Heidi Fettke, Chao Dai, Edmond M Kwan, et al.
BJU International
|
November 13, 2022
Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer
Richard Kelly, Andrew Jensen, Nathasha Karunaratna, et al.
Page
of 36